Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Shares Issued (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Shares Issued for 5 consecutive years, with $15.7 million as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 152.35% to $15.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $22.7 million for FY2025, N/A changed from the prior year.
  • Shares Issued hit $15.7 million in Q4 2025 for Krystal Biotech, up from $3.7 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $202.1 million in Q4 2021 to a low of -$118.7 million in Q3 2023.
  • Historically, Shares Issued has averaged $21.5 million across 5 years, with a median of $2.4 million in 2023.
  • Biggest five-year swings in Shares Issued: soared 15527.14% in 2022 and later tumbled 5697.83% in 2023.
  • Year by year, Shares Issued stood at $202.1 million in 2021, then tumbled by 112.83% to -$25.9 million in 2022, then soared by 110.07% to $2.6 million in 2023, then tumbled by 1248.79% to -$30.0 million in 2024, then skyrocketed by 152.35% to $15.7 million in 2025.
  • Business Quant data shows Shares Issued for KRYS at $15.7 million in Q4 2025, $3.7 million in Q3 2025, and $1.8 million in Q2 2025.